

Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
10-12 April 2012
CCV/CICG, Geneva

Tuesday, 10 April 2012

Time	Session	Purpose of session, target outcomes and questions for SAGE	
9:00	Welcome - introduction H. Rees, Chair of SAGE		20 min.
9:20	Report from Director, IVB - Session 1 Global report including key updates and challenges from regions, J.-M. Okwo-Bele, WHO, 30 min. Discussion: 1 h 30 min.	FOR INFORMATION	2 h
10:30	Coffee/tea break	Break	30 min.
11:00	Report from Director, IVB - Session 1 (Contd.)		
11:50	Reports from other Advisory Committees on Immunization - Session 2 Report of the Global Advisory Committee on Vaccine Safety (GACVS), M. Wharton, Chair of GACVS, 10 min. Discussion: 20 min.	FOR INFORMATION	30 min.
12:20	Lunch	Break	1 h 10 min.
13:30	Polio eradication - Session 3 Global polio eradication initiative (GPEI) Emergency Action Plan 2012-13: planned corrective actions in 'off-track' countries - Introduction, B. Aylward, WHO, 5 min. - Pakistan, S. Wazir Ali, Special Assistant to the Prime Minister/ Co-Chair Pakistan Education Task Force, Government of Pakistan, Islamabad, by phone link, 15 min.	FOR DISCUSSION AND DECISION Does SAGE feel that the planned actions in Nigeria, Pakistan, and Afghanistan address the main gaps?	3 h

	<p>- Nigeria, M. Ado on behalf of . M. Pate, Honourable Minister of State for Health, Federal Ministry of Health, Abuja, Nigeria, by phone link, 15 min.</p> <p>Discussion: 10 min.</p>		
	<p>Discussion: 10 min.</p> <p>- Afghanistan, M.T. Mashal, Director General Preventive Medicine, Ministry of Public Health, Kabul, Afghanistan, by phone link, 15 min.</p> <p>Discussion: 10 min.</p> <p>- Prioritizing emergency polio eradication activities in view of the chronic financing gap, H. Jafari, WHO, 15 min.</p> <p>Discussion: 25 min.</p>	<p>Does SAGE concur with the suggested order of priorities for emergency activities in response to the financing gap?</p>	
15:30	Coffee/tea break	Break	30 min.
16:00	<p>Polio eradication - Session 3 (Contd.)</p> <p>The tOPV - bOPV switch and suggested IPV policy to complete type 2 eradication, P. Figueroa, member of the SAGE Working Group on polio, 20 min.</p> <p>Discussion: 40 min.</p>	<p>FOR DECISION</p> <p>SAGE to consider specific recommendations for the synchronous replacement of tOPV with bOPV for routine immunization globally by April 2014, preceded 6 months beforehand by the introduction of a supplementary dose of IPV (given IM or as a fractional dose ID) at the DPT3 contact.</p>	
17:00	Cocktail		

Wednesday, 11 April 2012

08:30	<p>Seasonal influenza vaccine - Session 4</p> <p>Global influenza burden of disease, J. Bresee, member of the SAGE Working Group on influenza vaccines and immunization, by phone link, 15 min.</p> <p>Influenza vaccine effectiveness, J. Englund, member of the SAGE Working Group on influenza vaccines and immunization, 15 min.</p> <p>Safety of influenza vaccines, P. Lambach, WHO, 10 min.</p> <p>Presentation of recommendations, A. Reingold, member of SAGE Working Group on influenza vaccines and immunization, 15 min.</p> <p>Discussion: 1 h 35 min.</p>	<p>FOR DECISION</p> <p>SAGE recommendations on the use of seasonal influenza vaccines with particular focus on key target groups.</p> <p>SAGE recommendation on prioritization of immunization for risk groups.</p> <p>SAGE recommendations on the need to update the 2003 WHA coverage goals and to set specific coverage goals in various target groups.</p>	2 h 30 min.
10:00	Coffee/tea break	Break	30 min.
10:30	Seasonal influenza vaccine - Session 4 (Contd.)		
11:30	<p>Impact of introduction of new vaccines on the strengthening of immunization and health systems - Session 5</p> <p>Brief introduction to the session, D. Durrheim, member of SAGE, 5 min.</p> <p>Summary of findings from literature reviews and assessments and interviews in the context of the WHO Health System Building Blocks Framework, T. Hyde, US Centers for Disease control and Prevention, 25 min.</p> <p>Review of findings and gaps in information on impact of new vaccines on immunization and health systems, N. Arora, member of SAGE, 10 min.</p> <p>Discussion: Focus on findings and evidence gaps, 35 min.</p>	<p>FOR DISCUSSION</p> <p>SAGE is requested to comment on this completed review of existing data and flag evidence gaps.</p>	2 h
12:45	Lunch	Break	1 h
13:45	<p>Impact of introduction of new vaccines on the strengthening of immunization and health systems - Session 5 (Contd.)</p> <p>Principles for new vaccine introduction, D. Durrheim, member of SAGE, 10 min.</p> <p>A practical tool for countries, updated WHO document entitled: <i>"Principles and Considerations for Adding a Vaccine to a National Immunization Programme"</i>, S. Wang, WHO, 10 min.</p> <p>Discussion of principles and specific sections of the updated WHO document, 25 min.</p>	<p>SAGE is requested to endorse the principles and to review and provide comments on the relevant sections of the updated WHO document <i>"Principles and Considerations for Adding a Vaccine to a National Immunization Programme"</i>.</p>	

14:30	<p>Vaccination in humanitarian emergencies - Session 6</p> <p>Brief introduction of the process that is being followed for the development of the framework, H. Rees, Chair of SAGE Working Group on vaccination in humanitarian emergencies, 5 min.</p> <p>Literature review of vaccination experience in previous humanitarian emergencies /Existing recommendations and guidance, Z. Bhutta, member of the SAGE Working Group on vaccination in humanitarian emergencies, 15 min.</p> <p>Discussion: 25 min.</p> <p>Ethical issues surrounding use of vaccines in emergency settings, K. Moodley, member of the SAGE Working Group on vaccination in humanitarian emergencies, 10 min.</p> <p>Discussion: 15 min.</p>	<p>FOR DISCUSSION</p> <p>Provide an update from SAGE working group on use of vaccination in humanitarian emergencies.</p> <p>Present SAGE with the outcome of the literature review, lessons learnt from case studies, and completed ethical perspective in support of the use of vaccination in humanitarian emergencies.</p> <p>Discuss and get concurrence from SAGE or suggestions for modifications on the proposed "Vaccination in acute humanitarian emergencies: a framework for decision-making".</p> <p>Get SAGE's input on activities necessary to facilitate the further buy in and use of the framework.</p>	2 h 30 min.
15:30	Coffee/tea break	Break	30 min.
16:00	<p>Vaccination in humanitarian emergencies - Session 6 (Contd.)</p> <p>Vaccination in acute humanitarian emergencies: a framework for decision-making, R. Waldman, member of the SAGE working group on use of vaccination in humanitarian emergencies, 20 min.</p> <p>Discussion: 1 h 10 min.</p>		
17:30	End of meeting		

Thursday, 12 April 2012

08:30	<p>Rotavirus vaccines schedules - Session 7</p> <p>Optimizing rotavirus schedules: what are the key questions for today's session? P. Fine, London School of Hygiene and Tropical Medicine, 5 min.</p> <p>Rotavirus vaccine effectiveness after 2 or 3 doses and risk of Intussusception after rotavirus vaccination, U. Parashar, US Centres for Disease Control and Prevention, 15 min.</p> <p>Rotavirus vaccination: tailoring the immunization schedule to the local epidemiology and operational realities, C. Sanderson, London School of Hygiene and Tropical Medicine, 15 min.</p> <p>Benefits of mortality reduction versus risk of fatal intussusception, M. Patel, US Centres for Disease Control and Prevention, 15 min.</p> <p>Overview of major conclusions from the ad hoc group of experts, J. Abramson, member of SAGE, 10 min.</p> <p>Discussion: 1 h</p>	<p>FOR DECISION</p> <p>Present SAGE with available evidence on the benefits and risks of the current (and alternative) rotavirus immunization schedules for children living in different income strata/mortality settings?</p> <p>Secure SAGE recommendations on the optimal schedules for rotavirus vaccines for children living in different income strata/mortality settings?</p>	2 h
10:30	Coffee/tea break	Break	30 min.
11:00	<p>Use of hepatitis A vaccines: Evidence and recommendations on the flexibility of a booster dose of inactivated hepatitis A vaccine with focus on long-term protection achieved by single dose administration - Session 8</p> <p>Impact and monitoring the impact of single dose hepatitis A vaccine use in Argentina, C. Vizzotti, Ministry of Health, Argentina, 15 min.</p> <p>Process of evidence and data collection and overview of evidence obtained including GRADE tables, D. Shouval, Hadassah Hebrew University Hospital, Israel, 20 min.</p> <p>Draft recommendations for flexible use of inactivated hepatitis A vaccine booster dose, A. Reingold, Chair of hepatitis A WG, 10 min.</p> <p>Discussion: 55 min.</p>	<p>FOR DECISION</p> <p>In addition to previous recommendations on the use of hepatitis A vaccines, and which it will not be asked to revisit, SAGE will be asked to specifically answer the following question:</p> <p>Is a single dose vaccination with inactivated hepatitis A sufficient enough to provide long-term protection?</p>	1 h 30 min.
12:30	Lunch	Break	1 h

13:30	<p>Report from the GAVI Alliance Secretariat - Session 9</p> <p>Report from GAVI Alliance, S. Berkley, GAVI Alliance, 20 min.</p> <p>Discussion: 20 min.</p>	FOR INFORMATION	40 min.
14:10	<p>Information on vaccines for an Intergovernmental Negotiating Committee on Mercury - Session 10</p> <p>Outcomes from a WHO Informal Consultation (3-4 April) on further guidance on vaccines in preparation for the fourth Intergovernmental Negotiating Committee (INC4). E. Griffiths, Chair of the consultation, 30 min.</p> <p>Perspectives from stakeholders countries, C. Ruiz-Matus, WHO, 10 min.</p> <p>Manufacturers perspective, S. Jadhav, Developing Countries Vaccine Manufacturers Network, 10 min.</p> <p>Potential guidance to countries on vaccines for the mercury-treaty negotiations, D. Wood, WHO, 10 min.</p> <p>Discussion: 1 h</p>	<p>FOR DISCUSSION</p> <p>In the context of the INC process, countries have asked WHO for information on alternative preservatives for vaccines and the economic, programmatic and manufacturing implications of moving (globally) to single-dose, preservative-free vaccines.</p> <p>SAGE will be requested to help formulate such guidance. The safety of alternative preservatives will be reviewed by GACVS in June 2012.</p>	2 h
16:10	Closing		20 min.
16:30	End of meeting		